News and Trends 23 May 2018 Grass Pollen Allergy Vaccine Gets Encouraging Phase II Results Allergy Therapeutics has obtained positive Phase II results for its grass pollen allergy vaccine and plans to launch a Phase III study next year. British biotech Allergy Therapeutics has obtained positive Phase II results for its grass pollen allergy vaccine. Roughly 30% of the population in Europe are allergic to grass pollen. The company plans […] May 23, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
Startup Scout 9 Mar 2018 This Portugese Biotech is Developing a Vaccine for Life-Threatening Multibacterial Infections This week, we’re in Cantanhede, a small city near the coast in Portugal, to visit Immunethep. The company is developing immunotherapies against life-threatening multibacterial infections using a virulence mechanism common to different types of bacteria. Mission: Founded in 2014, Immunethep is a spin-off from the University of Porto that discovered a novel virulence mechanism by which bacteria suppress the […] March 9, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 7 Mar 2018 Oxford Keeps Growing as a Hotspot for Cancer Vaccines with New Fundraising Oxford Vacmedix has secured $12.5M (€10M) to start its first clinical trials, joining other Oxford-based biotechs in the cancer vaccine field such as Vaccitech and SpyBiotech. Oxford Vacmedix has secured Series A financing to continue the development of its two lead cancer vaccines to target cervical cancer and other solid tumors. The financing round represents the […] March 7, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 26 Feb 2018 This Oral Vaccine for Typhoid Raises €8M from International Investors Prokarium has raised $10M (€8M) from Saudi, Swedish and Korean investors to support the clinical development of its oral vaccines for infectious diseases like typhoid. Since its foundation in 2012, Prokarium has been working on oral vaccines and it has developed a delivery platform that can be applied to any antigen used for vaccination. The biotech has […] February 26, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Interview 7 Feb 2018 Hookipa CEO “Sleeps Quite Well at Night” with €50M Cash Pile and Cancer Vaccine Progress Did you miss us in Vienna? Here’s the first of our two interviews from the Refresh meetup last month: Jörn Aldag, CEO of Hookipa, talked to us about the importance of a sound financial strategy and where cancer vaccines are on the hype curve. Jörn Aldag has had quite a career. His first position as […] February 7, 2018 - 4 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 16 Jan 2018 Dutch Biotech Joins International Effort to Eradicate Polio Batavia Biosciences joins an international consortium to develop and manufacture a safer type of polio vaccine. Their ultimate goal is to eradicate the disease. Based in Leiden, the Netherlands, Batavia Biosciences specializes in the development and production of viruses and proteins. Its expertise has attracted an international consortium to recruit Batavia in their effort to […] January 16, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 16 Jan 2018 Young Oxford Biotech Raises €22.5M to Develop a Universal Flu Vaccine Vaccitech has closed a Series A fundraising that will support clinical trials with its vaccine technology against influenza and prostate cancer. Spun out from Oxford University in 2016, Vaccitech has now closed its Series A fundraising round. Amounting to a total of £20M (€22.5M), the round was co-led by GV, Oxford Sciences Innovation and Sequoia China, and joined […] January 16, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 18 Dec 2017 Dutch and US Biotechs Team Up Against HPV-related Cancer ISA Pharmaceuticals will work together with Regeneron to combine its immunotherapy against cancer induced by HPV infection with its partner’s PD-1 checkpoint inhibitor. The human papillomavirus (HPV) is known for its ability to cause cancer, including cervical and head and neck cancer. Based in Leiden, the Netherlands, ISA Pharmaceuticals’ target choice is type 16 HPV, which […] December 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 14 Dec 2017 Someone’s Popular! Gilead is Just One Big Name Investing in this Vaccine Biotech Gilead has joined a growing list of powerful investors that want to help Hookipa Biotech develop its vaccine technology by participating in its Series C fundraising. Hookipa Biotech, one of October’s biotechs of the week, develops vaccines for cancer and infectious diseases. Its pipeline includes two platforms: Vaxwave and TheraT, which are targeted at cytomegalovirus infections and […] December 14, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 5 Dec 2017 The Philippines Blocks Sanofi’s Dengue Vaccine for Safety Reasons Following alarming research about the safety of Sanofi’s dengue vaccine, Dengvaxia, The Philippines has halted its sale, distribution and marketing “to protect the general public.” Before Sanofi Pasteur distributed its dengue vaccine, Dengvaxia, there were some concerns that it would make people sicker. Last year, researchers from top American and British institutions confirmed these suspicions […] December 5, 2017 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 16 Nov 2017 German Scientists Test Out New HIV Vaccine Combinations in Animals Scientists from the German Primate Center have investigated the impact of the delivery route and order of components on the success of an HIV vaccine. With more than 36 million people infected with the human immunodeficiency virus (HIV) and a further 2.4 million infected each year, something needs to be done. Researchers from the German […] November 16, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 6 Nov 2017 Austrian Biotech’s Vaccine Against Tropical Virus Moves Nicely Through Phase II Chikungunya fever could be the next big global outbreak. Reassuringly, Themis’ vaccine has so far performed well in a Phase II study. Vienna-based biotech, Themis, develops urgently needed vaccines against diseases, which have the potential to be the next global outbreak. The company has announced encouraging preliminary Phase II results for its vaccine against chikungunya […] November 6, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email